Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
2(33%)
Results Posted
0%(0 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
3
50%
Ph phase_3
3
50%

Phase Distribution

0

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
3(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(3)
Terminated(1)

Detailed Status

Completed3
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (50.0%)
Phase 33 (50.0%)

Trials by Status

terminated117%
completed350%
recruiting233%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_2

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

NCT05886660
recruitingphase_2

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

NCT05852730
completedphase_3

Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

NCT05548270
completedphase_3

Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

NCT04947423
terminatedphase_2

DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness

NCT04219982
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05886660Phase 2

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

Recruiting
NCT05852730Phase 2

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

Recruiting
NCT05548270Phase 3

Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

Completed
NCT04947423Phase 3

Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

Completed
NCT04219982Phase 2

DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness

Terminated
NCT04184115Phase 3

Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6